A Brand New CAR

1. Chang, P. S., Lee, J. C., Koneru, M. & Brentjens, R. J. 408. CD19-Targeted CAR T Cells “Armored” To Secrete IL-12 Demonstrate Superior Efficacy Against B Cell Acute Lymphoblastic Leukemia and Resist Treg Immunosuppression. Mol. Ther. 23, S161 (2015).

2. Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).

3. Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).

4. Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M. & Kobold, S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer 120, 26–37 (2019).

5. Tomasik, J., Jasiński, M. & Basak, G. W. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front. Immunol. 13, (2022).

6. Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. 86, 10024–10028 (1989).

7. Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–626 (1998).

8. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).

9. Roselli, E. et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J. Immunother. Cancer 9, e003354 (2021).

10. Penn, I. Occurrence of cancer in immune deficiencies. Cancer 34, 858–866 (1974).

11. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).